Porton(SZ:300363)2026-01-05 15:18Group 1: Financial Performance - The overall operating performance for 2025 is in line with the annual business plan, with specific results to be disclosed later [1] - The gross profit margin for the first three quarters of this year is approximately 29%, with a goal to continue improving this margin [3] Group 2: Market and Production Capacity - In 2025, the Chinese innovative drug market transaction amount exceeded $1.3 billion, boosting domestic market enthusiasm and demand, although competition remains strong with no significant price changes [1] - The overall capacity utilization rate of the company improved in 2025, focusing on utilizing existing capacity and assets, with capital expenditures (Capex) aimed at enhancing specific capabilities and facility upgrades [2][3] Group 3: Business Development and Innovation - The company achieved significant breakthroughs in various business areas, including commercial process changes and the development of in vivo CAR-T projects, with successful deliveries in overseas markets such as the US, Europe, and South Korea [3][4] - The company currently has a pilot-scale production capacity for small nucleic acids, sufficient to meet clinical phase II demand [5] Group 4: Operational Efficiency - The company aims to maintain a direction of cost reduction and efficiency improvement, with a net increase in personnel in 2025 while controlling expense growth in line with revenue increases [7]